CL2023000315A1 - Composición farmacéutica de corticosteroide intraarticular para el control del dolor - Google Patents
Composición farmacéutica de corticosteroide intraarticular para el control del dolorInfo
- Publication number
- CL2023000315A1 CL2023000315A1 CL2023000315A CL2023000315A CL2023000315A1 CL 2023000315 A1 CL2023000315 A1 CL 2023000315A1 CL 2023000315 A CL2023000315 A CL 2023000315A CL 2023000315 A CL2023000315 A CL 2023000315A CL 2023000315 A1 CL2023000315 A1 CL 2023000315A1
- Authority
- CL
- Chile
- Prior art keywords
- intra
- pharmaceutical composition
- articular corticosteroid
- pain control
- articular
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000006820 Arthralgia Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporciona un método de tratamiento del dolor articular en un sujeto con artritis. El método comprende la administración al sujeto, que sufre de un grado determinado de osteoartritis, de una cantidad efectiva de corticosteroide intraarticular, o una sal farmacéuticamente aceptable del mismo, en una composición farmacéutica. Se logra solidez de la respuesta de eficacia a un tratamiento con corticosteroide intraarticular en subgrupos predeterminados de la población de intención de tratar.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063061395P | 2020-08-05 | 2020-08-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023000315A1 true CL2023000315A1 (es) | 2023-09-22 |
Family
ID=77519828
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023000315A CL2023000315A1 (es) | 2020-08-05 | 2023-02-01 | Composición farmacéutica de corticosteroide intraarticular para el control del dolor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230285293A1 (es) |
| EP (1) | EP4192426A1 (es) |
| JP (1) | JP2023537474A (es) |
| KR (1) | KR20230048066A (es) |
| CN (1) | CN116348093A (es) |
| AU (1) | AU2021320774A1 (es) |
| BR (1) | BR112023001926A2 (es) |
| CA (1) | CA3187955A1 (es) |
| CL (1) | CL2023000315A1 (es) |
| IL (1) | IL300354A (es) |
| MX (1) | MX2023001410A (es) |
| TW (1) | TW202220668A (es) |
| WO (1) | WO2022031898A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022500364A (ja) | 2018-09-16 | 2022-01-04 | ティーエルシー バイオファーマシューティカルズ、インク． | 関節への送達に適した医薬組成物及びその関節痛の治療における使用 |
-
2021
- 2021-08-05 KR KR1020237006338A patent/KR20230048066A/ko unknown
- 2021-08-05 AU AU2021320774A patent/AU2021320774A1/en active Pending
- 2021-08-05 EP EP21762258.8A patent/EP4192426A1/en active Pending
- 2021-08-05 BR BR112023001926A patent/BR112023001926A2/pt unknown
- 2021-08-05 CN CN202180057600.XA patent/CN116348093A/zh active Pending
- 2021-08-05 MX MX2023001410A patent/MX2023001410A/es unknown
- 2021-08-05 CA CA3187955A patent/CA3187955A1/en active Pending
- 2021-08-05 JP JP2023507244A patent/JP2023537474A/ja active Pending
- 2021-08-05 TW TW110128943A patent/TW202220668A/zh unknown
- 2021-08-05 US US18/040,454 patent/US20230285293A1/en active Pending
- 2021-08-05 WO PCT/US2021/044619 patent/WO2022031898A1/en active Application Filing
- 2021-08-05 IL IL300354A patent/IL300354A/en unknown
-
2023
- 2023-02-01 CL CL2023000315A patent/CL2023000315A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022031898A1 (en) | 2022-02-10 |
| TW202220668A (zh) | 2022-06-01 |
| BR112023001926A2 (pt) | 2023-03-07 |
| CN116348093A (zh) | 2023-06-27 |
| KR20230048066A (ko) | 2023-04-10 |
| CA3187955A1 (en) | 2022-02-10 |
| EP4192426A1 (en) | 2023-06-14 |
| MX2023001410A (es) | 2023-03-06 |
| AU2021320774A1 (en) | 2023-03-09 |
| JP2023537474A (ja) | 2023-09-01 |
| IL300354A (en) | 2023-04-01 |
| US20230285293A1 (en) | 2023-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003542A1 (es) | Métodos de tratamiento para la fibrosis quística. | |
| MX2020007853A (es) | Composiciones farmaceuticas para el tratamiento de fibrosis quistica. | |
| CR20210563A (es) | Compuestos y métodos para el tratamiento de covid-19 | |
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
| ECSP20069416A (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| CO6630086A2 (es) | Tratamiento de artritis por lupus usando laquinimod | |
| EA200870469A1 (ru) | Новые, содержащие нимесулид, фармацевтические композиции с низкой дозой, их получение и применение | |
| AR074313A1 (es) | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo. uso. kit | |
| EA202190544A1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| AR127247A1 (es) | Inhibidores de cdk2 de ciclopentilpirazol | |
| AR119033A1 (es) | Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa | |
| CL2023000315A1 (es) | Composición farmacéutica de corticosteroide intraarticular para el control del dolor | |
| MX2021007330A (es) | Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia. | |
| EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
| BR112022025920A2 (pt) | Tratamento de artrite reumatoide | |
| RU2015114709A (ru) | Стабильная композиция для инъекций, содержащая диклофенак и тиоколхикозид | |
| CL2021003303A1 (es) | Tratamiento para sinucleinopatías. | |
| BR112022019493A2 (pt) | Cocristal de gabapentina, cetoprofeno e lisina, composições farmacêuticas e seu uso médico | |
| MX2021003030A (es) | Composiciones farmaceuticas adecuadas para suministro articular y su uso en tratamiento de dolor de articulacion. | |
| AR101227A1 (es) | Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor | |
| Popov et al. | Optimal use of hyaluronic acid for joint pathology treatment | |
| AR120453A1 (es) | Combinación de un inhibidor de btk y un inhibidor de mdm2 para el tratamiento del cáncer | |
| EA202092944A1 (ru) | Применение пероральных распадающихся таблеток рилузола для лечения заболеваний | |
| BR112022006267A2 (pt) | Método para tratar hiv com cabotegravir e rilpivirina |